Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All vitamin D studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchVitamin DVitamin D (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality -5% Improvement Relative Risk Mortality (b) 45% Oxygen therapy 55% Hospitalization 4% Vitamin D for COVID-19  Gavioli et al.  Sufficiency Are vitamin D levels associated with COVID-19 outcomes? Retrospective 437 patients in the USA Lower need for oxygen therapy with higher vitamin D levels (p=0.0002) c19early.org Gavioli et al., J. the American Colleg.., Feb 2021 Favors vitamin D Favors control

An Evaluation of Serum 25-Hydroxy Vitamin D Levels in Patients with COVID-19 in New York City

Gavioli et al., Journal of the American College of Nutrition, doi:10.1080/07315724.2020.1869626
Feb 2021  
  Post
  Facebook
Share
  Source   PDF   All   Meta
Vitamin D for COVID-19
8th treatment shown to reduce risk in October 2020
 
*, now known with p < 0.00000000001 from 119 studies, recognized in 7 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,900+ studies for 60+ treatments. c19early.org
Retrospective 437 mostly serious condition (85% hospitalized) patients in New York, showing vitamin D deficiency associated with increased likelihood of oxygen support, but no association with mortality and hospitalization. Multivariate analysis excluded variables with p > 0.2 in univariate analysis. Adjustment for factors correlated with vitamin D may obscure the effect of vitamin D levels.
This is the 49th of 192 COVID-19 sufficiency studies for vitamin D, which collectively show higher levels reduce risk with p<0.0000000001 (1 in 611 vigintillion).
risk of death, 4.7% higher, RR 1.05, p = 0.83, high D levels 80 of 260 (30.8%), low D levels 52 of 177 (29.4%), >20ng/ml.
risk of death, 44.8% lower, RR 0.55, p < 0.001, high D levels 102 of 376 (27.1%), low D levels 30 of 61 (49.2%), NNT 4.5, >10ng/ml.
risk of oxygen therapy, 55.2% lower, RR 0.45, p < 0.001, high D levels 127 of 260 (48.8%), low D levels 116 of 177 (65.5%), NNT 6.0, adjusted per study, inverted to make RR<1 favor high D levels, >20ng/ml, multivariate.
risk of hospitalization, 3.6% lower, RR 0.96, p = 0.41, high D levels 218 of 260 (83.8%), low D levels 154 of 177 (87.0%), NNT 32, >20ng/ml.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Gavioli et al., 19 Feb 2021, retrospective, USA, peer-reviewed, 4 authors.
This PaperVitamin DAll
An Evaluation of Serum 25-Hydroxy Vitamin D Levels in Patients with COVID-19 in New York City
Elizabeth Marie Gavioli, Hirotaka Miyashita, Omar Hassaneen, Evan Siau
Journal of the American Nutrition Association, doi:10.1080/07315724.2020.1869626
Aim: Deterioration of patients from COVID-19 is associated with cytokine release syndrome attributed to an elevation in pro-inflammatory cytokines. Vitamin D reduces proinflammatory cytokines, and has the possibility of reducing complications from respiratory tract illnesses. Method: This was a retrospective, observational, cohort study of patients with COVID-19 disease within a New York City Health System. Adult patients were included if they tested positive for SARS-CoV-2, and had a serum 25-hydroxy vitamin D level (25(OH)D) within the three previous months prior to their detected SARS-CoV-2 test. Patients were compared and evaluated based upon their 25(OH)D levels. The primary endpoints were hospitalization, need for oxygen support, and 90-day mortality. Results: 437 COVID-19 patients were included [67 (IQR: 56-79) years] within this cohort. Deficient plasma 25(OH)D levels (<20 ng/ml) were associated with an increased likelihood of oxygen support [OR:2.23 (95% CI: 1.46-3.44, p ¼ 0.0002)] from COVID-19. Deficient plasma 25(OH)D levels were not independently associated with 90-day mortality or risk of hospitalization. Hospitalization rates (98%), oxygen support (93%), and mortality rates (49%) were highest in patients who had 25(OH)D levels less than 10 ng/ml when compared to other 25(OH)D levels. Conclusion: Serum 25-hydroxy vitamin D levels may affect the need for oxygen support therapy in patients with COVID-19.
Disclosure statement The authors declare that they do not have a conflict of interest. Appendix A. Multivariate analysis between 25(OH)D levels and outcomes from COVID-19 infection
References
Abrishami, Dalili, Torbati, Asgari, Arab-Ahmadi et al., Possible association of vitamin D status with lung involvement and outcome in patients with COVID-19: a retrospective study, Eur J Nutr, doi:10.1007/s00394-020-02411-0
Aihara, Azuma, Akaike, Ikeda, Yamashita et al., Disruption of nuclear vitamin D receptor gene causes enhanced thrombogenicity in mice, J Biol Chem, doi:10.1074/jbc.M404865200
Alquaiz, Kazi, Fouda, Alyousefi, Age and gender differences in the prevalence and correlates of vitamin D deficiency, Arch Osteoporos, doi:10.1007/s11657-018-0461-5
Annweiler, Corvaisier, Gautier, Dub Ee, Legrand et al., Vitamin D supplementation associated to better survival in hospitalized frail elderly COVID-19 patients: The GERIA-COVID quasi-experimental study, Nutrients, doi:10.3390/nu12113377
Arvinte, Singh, Marik, Serum levels of vitamin C and vitamin D in a cohort of critically ill COVID-19 patients of a North American Community Hospital Intensive Care Unit in May 2020: a pilot study, Med Drug Discov, doi:10.1016/j.medidd.2020.100064
Aygun, Vitamin D can prevent COVID-19 infection-induced multiple organ damage, Naunyn Schmiedebergs Arch Pharmacol, doi:10.1007/s00210-020-01911-4
D'avolio, Avataneo, Manca, Cusato, Nicol O et al., 25-Hydroxyvitamin D concentrations are lower in patients with positive PCR for SARS-CoV-2, Nutrients, doi:10.3390/nu12051359
De Lucena, Da, Santos, De Lima, De et al., Mechanism of inflammatory response in associated comorbidities in COVID-19, Diabetes Metab Syndr, doi:10.1016/j.dsx.2020.05.025
Grimes, Schulz, False alarms and pseudo-epidemics: the limitations of observational epidemiology, Obstet Gynecol, doi:10.1097/AOG.0b013e31826af61a
Guo, Cao, Hong, Tan, Chen et al., The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak -an update on the status, Mil Med Res, doi:10.1186/s40779-020-00240-0
Han, Jones, Tangpricha, Brown, Brown et al., High dose vitamin D administration in ventilated intensive care unit patients: a pilot double blind randomized controlled trial, J Clin Transl Endocrinol, doi:10.1016/j.jcte.2016.04.004
Ilie, Stefanescu, Smith, The role of vitamin D in the prevention of coronavirus disease 2019 infection and mortality, Aging Clin Exp Res, doi:10.1007/s40520-020-01570-8
Ishimura, Nishizawa, Inaba, Matsumoto, Emoto et al., Serum levels of 1,25-dihydroxyvitamin D, 24,25-dihydroxyvitamin D, and 25-hydroxyvitamin D in nondialyzed patients with chronic renal failure, Kidney Int, doi:10.1046/j.1523-1755.1999.0550031019.x
Jain, Parsanathan, Can vitamin D and L-cysteine co-supplementation reduce 25(OH)-vitamin D deficiency and the mortality associated with COVID-19 in African Americans?, J Am Coll Nutr, doi:10.1080/07315724.2020.1789518
Khoo, Chai, Koenen, Joosten, Netea et al., Translating the role of vitamin D3 in infectious diseases, Crit Rev Microbiol, doi:10.3109/1040841X.2011.622716
Kumar, Gupta, Banerjee, Letter: does vitamin D have a potential role against COVID-19?, Aliment Pharmacol Ther, doi:10.1111/apt.1580
Laclair, Hellman, Karp, Kraus, Ofner et al., Prevalence of calcidiol deficiency in CKD: a cross-sectional study across latitudes in the United States, Am J Kidney Dis, doi:10.1053/j.ajkd.2005.02.029
Martineau, Jolliffe, Greenberg, Aloia, Bergman et al., Vitamin D supplementation to prevent acute respiratory infections: individual participant data meta-analysis, Health Technol Assess, doi:10.3310/hta23020
Merzon, Tworowski, Gorohovski, Vinker, Cohen et al., Low plasma 25(OH) vitamin D level is associated with increased risk of COVID-19 infection: an Israeli population-based study, FEBS J, doi:10.1111/febs.15495
Mikami, Miyashita, Yamada, Risk factors for mortality in patients with COVID-19 in New York City
Mohammad, Mishra, Ashraf, Emerging role of vitamin D and its associated molecules in pathways related to pathogenesis of thrombosis, Biomolecules, doi:10.3390/biom9110649
Moulas, Vaiou, Vitamin D fortification of foods and prospective health outcomes, J Biotechnol, doi:10.1016/j.jbiotec.2018.08.010
Ohaegbulam, Swalih, Patel, Smith, Perrin, Vitamin D supplementation in COVID-19 patients: a clinical case series, Am J Ther, doi:10.1097/MJT.0000000000001222
Panarese, Shahini, Letter: Covid-19, and vitamin D, Aliment Pharmacol Ther, doi:10.1111/apt.15752
Rajakumar, De Las Heras, Chen, Lee, Holick et al., Vitamin D status, adiposity, and lipids in black American and Caucasian children, J Clin Endocrinol Metab, doi:10.1210/jc.2010-2388
Rastogi, Bhansali, Khare, Suri, Yaddanapudi et al., Short term, high-dose vitamin D supplementation for COVID-19 disease: a randomised, placebo-controlled, study (SHADE study), Postgrad Med J, doi:10.1136/postgradmedj-2020-139065
Vyas, Kurian, Bagchi, Manu, Saravu et al., Vitamin D in prevention and treatment of COVID-19: current perspective and future prospects, J Am Coll Nutr, doi:10.1080/07315724.2020
Wang, Degruttola, Lei, Mayer, Redline et al., The vitamin D for COVID-19 (VIVID) trial: a pragmatic cluster-randomized design, Contemp Clin Trials, doi:10.1016/j.cct.2020.106176
Yang, Gu, Zhao, Wang, Cao et al., Angiotensin-converting enzyme 2 (ACE2) mediates influenza H7N9 virus-induced acute lung injury, Sci Rep, doi:10.1038/srep07027
Zhou, Yu, Du, Fan, Liu et al., Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet, doi:10.1016/S0140-6736(20)30566-3
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit